Oral ciprofloxacin vs. intramuscular ceftriaxone as empiric treatment of acute invasive diarrhea in children

Pediatric Infectious Disease Journal

Volumn 19, Issue 11, 2000, Pages 1060-1067

  Leibovitz, Eugene ^a   Janco, Jacob ^a   Piglansky, Lolita ^a   Press, Joseph ^a   Yagupsky, Pablo ^a   Reinhart, Heinz ^c   Yaniv, Irit ^b   Dagan, Ron ^a  

^a BEN GURION UNIVERSITY OF THE NEGEV   (Israel)

^b Pharma Clinical   (Israel)

^c BAYER CORPORATION   (United States)

Author keywords

Acute invasive diarrhea; Ceftriaxone; Children; Ciprofloxacin; Minimal inhibitory concentration

Indexed keywords

CEFTRIAXONE; CIPROFLOXACIN;

ACUTE DIARRHEA; ARTICLE; CAMPYLOBACTER; CHILD; CHILDHOOD DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; FEMALE; HUMAN; INFANT; MAJOR CLINICAL STUDY; MALE; MINIMUM INHIBITORY CONCENTRATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SALMONELLA; SHIGELLA; SUSPENSION; TREATMENT OUTCOME;

ACUTE DISEASE; ADMINISTRATION, ORAL; ADOLESCENT; ANTI-INFECTIVE AGENTS; CEFTRIAXONE; CEPHALOSPORINS; CHILD; CHILD, PRESCHOOL; CIPROFLOXACIN; DIARRHEA; DOUBLE-BLIND METHOD; FEMALE; HUMANS; INFANT; INFANT, NEWBORN; INJECTIONS, INTRAMUSCULAR; MALE; PROSPECTIVE STUDIES;

EID: 0033678562     PISSN: 08913668     EISSN: None     Source Type: Journal    
DOI: 10.1097/00006454-200011000-00006     Document Type: Article

References (50)

1. The magnitude of the global problem of acute diarrhoeal disease: A review of active surveillance data
2. The burden of disease resulting from diarrhea
3. Global progress in the control of diarrheal disease
4. Fecal leukocytes in enteric infections
5. Role of stool screening tests in diagnosis of inflammatory bacterial enteritis and in selection of specimens likely to yield invasive enteric pathogens
6. Approach to patients with gastrointestinal tract infections and food poisoning
7. Antibiotic treatment of bacterial gastroenteritis
8. Acute infectious enteritis in children: Emergency department diagnosis and management
9. Therapy for shigellosis: I. Randomized, double-blind trial of nalidixic acid in childhood shigellosis
10. Antimicrobial therapy for shigellosis
11. Antimicrobial resistance in organisms causing diarrheal disease
12. Increasing antimicrobial resistance of Shigella isolates in Israel during the period 1984 to 1992
13. Plasmid-mediated resistance to nalidixic acid in Shigella dysenteriae type 1
14. Comparative efficacy of ceftriaxone and ampicillin for treatment of severe shigellosis in children
15. Prevalence of intestinal infections caused by diarrheagenic Escherichia coli in Bedouin infants and young children in Southern Israel
16. Capillary electrophoresis with laser-induced fluorescence detection, an adequate alternative to high-performance liquid chromatography, for the determination of ciprofloxacin and its metabolite desethyleneciprofloxacin in human plasma
17. The fluoroquinolones: Structure, mechanism of action and resistance, and spectra of activity in vitro
18. Clinical use of quinolones
19. Pharmacokinetics of ciprofloxacin after oral and parenteral administration
20. Pharmacokinetics of ciprofloxacin
21. Quinolone resistance: Susceptibility data from a 300-bed community hospital
22. Therapy for shigellosis: II. Randomized, double blind comparison of ciprofloxacin and ampicillin
23. Treatment of shigellosis: III. Comparison of one or two-dose ciprofloxacin with standard 5-day therapy: A randomized, blinded trial
24. Treatment of shigellosis: V. Comparison of azithromycin and ciprofloxacin: A double-blind, randomized, controlled trial
25. Quinolone antibiotics in the treatment of Salmonella infections
26. Antimicrobial therapy for enteric infections and typhoid fever
27. Randomized controlled comparison of a single-dose ciprofloxacin and doxycycline for cholera caused by Vibrio cholerae O1 or O139
28. The adverse effects of fluoroquinolones
29. Histologic and histochemical changes in articular cartilages of immature beagle dogs dosed with difloxacin, a fluoroquinolone
30. Quinolone arthropathy in animals versus children
31. Nalidixic acid in children: Retrospective matched controlled study for cartilage toxicity
32. Clinical, radiologic and magnetic resonance monitoring for skeletal toxicity in pediatric patients with cystic fibrosis receiving a three-month course of ciprofloxacin
33. Safety of ciprofloxacin in children: Worldwide clinical experience based on compassionate use: Emphasis on joint evaluation
34. Antipseudomonal therapy in cystic fibrosis: Aztreonam and amikacin versus ceftazidime and amikacin administered intravenously followed by oral ciprofloxacin
35. Use of fluoroquinolones for empirical management of febrile neutropenia in pediatric cancer patients
36. Oral ciprofloxacin in the management of chronic suppurative otitis media without cholesteatoma in children: Preliminary experience in 21 children
37. Use of fluoroquinolones in pediatrics: Consensus report of an International Society of Chemotherapy Commission
38. Ciprofloxacin in pediatrics; worldwide clinical experience based on compassionate use: Safety report
39. Quinolones in children with invasive salmonellosis
40. An open study of ciprofloxacin for the treatment of proven or suspected extra-intestinal salmonellosis in African children: A preliminary report
41. Ciprofloxacin for treatment of severe typhoid fever in children
42. Eradication of convalescent-phase Salmonella carriage in children with two oral doses of pefloxacin
43. Randomized comparison of ciprofloxacin suspension and pivmecillinam for childhood shigellosis
44. Epidemiology of Shigella infections in two ethnic groups in a geographic region in southern Israel
45. Quinolone resistant Campylobacter jejuni infections in Minnesota, 1992-1998
46. Single-dose and steady-state pharmacokinetics of a new oral suspension of ciprofloxacin in children
47. Pharmacokinetic/pharmacodynamic parameters: Rationale for antibacterial dosing of mice and men
48. Comparative antibiotic dose-effect relations at several dosing intervals in murine pneumonitis and thigh-infection models
49. Pharmacodynamics of intravenous ciprofloxacin in seriously ill patients
50. Prospective development of pharmacodynamic relationship between measures of levofloxacin exposure and measures of patient outcome